Skip to Main Content

Advertisement

Skip Nav Destination

Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies

Cancer Res (2022) 82 (4_Supplement): PD10-07.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Miquel Ensenyat-Mendez
  • Javier I. J. Orozco
  • Pere Llinàs-Arias
  • Sandra Íñiguez-Muñoz
  • Jennifer L. Baker
  • Matthew P. Salomon
  • Mercè Martí
  • Maggie L. DiNome
  • Javier Cortés
  • Diego M. Marzese
Communications Medicine (2023) 3 (1)
Close Modal

or Create an Account

Close Modal
Close Modal